Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.

@article{2006UpdateGS,
  title={Update: Guillain-Barr{\'e} syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.},
  author={},
  journal={MMWR. Morbidity and mortality weekly report},
  year={2006},
  volume={55 41},
  pages={
          1120-4
        }
}
    In October 2005, reports indicating a possible association between Guillain-Barré Syndrome (GBS) and receipt of meningococcal conjugate vaccine (MCV4) (Menactra, Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) were made to the Vaccine Adverse Event Reporting System (VAERS). GBS is a serious neurologic disorder involving inflammatory demyelination of the peripheral nerves. During March 2005-February 2006, eight confirmed cases had occurred within 6 weeks (i.e., the time window of elevated risk… CONTINUE READING
    2
    Twitter Mentions

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 15 CITATIONS

    Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.

    • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
    • 2008
    VIEW 3 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Epidemiology of Guillain-Barré syndrome in the province of Quebec.

    • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
    • 2008